BioSight
Companies
Disc Medicine, Inc. logo

IRON

NASDAQWATERTOWN, MA
Disc Medicine, Inc.

Disc Medicine develops drug candidates to treat blood disorders and other diseases using small-molecule therapeutics. The company is in early-stage development, with bitopertin among its product candidates in preclinical and clinical testing phases. Disc Medicine is pursuing regulatory approval and commercialization of its pipeline while seeking funding and potential strategic partnerships to support ongoing research and development.

Price history not yet available for IRON.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar